Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCMNYSE:HAENASDAQ:HQYNASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$83.86+1.1%$83.49$57.52▼$117.19$32.89B1.444.39 million shs500,664 shsHAEHaemonetics$76.22+1.4%$69.66$55.30▼$94.99$3.66B0.39669,757 shs19,668 shsHQYHealthEquity$103.34+1.5%$100.09$65.01▼$116.65$8.96B0.49860,020 shs78,411 shsLNTHLantheus$81.26+2.6%$82.10$73.11▼$126.89$5.62B0.121.02 million shs48,130 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+0.25%-4.98%-4.30%+36.66%-27.05%HAEHaemonetics-2.40%+0.31%+6.07%+34.20%-11.72%HQYHealthEquity+2.29%-2.80%-8.71%+32.64%+23.33%LNTHLantheus-0.03%-3.26%-2.89%-15.22%+0.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXCMDexCom4.8988 of 5 stars3.55.00.04.72.92.51.9HAEHaemonetics4.8802 of 5 stars4.52.00.04.32.61.72.5HQYHealthEquity3.6311 of 5 stars3.53.00.00.02.32.51.9LNTHLantheus4.4547 of 5 stars3.51.00.04.22.32.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.95Moderate Buy$98.5017.45% UpsideHAEHaemonetics 2.91Moderate Buy$96.8027.01% UpsideHQYHealthEquity 3.00Buy$118.0914.28% UpsideLNTHLantheus 3.00Buy$130.5060.60% UpsideCurrent Analyst Ratings BreakdownLatest HAE, DXCM, HQY, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025HAEHaemoneticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/25/2025HAEHaemoneticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/16/2025DXCMDexComTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$102.006/5/2025HQYHealthEquityBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $125.006/5/2025HQYHealthEquityDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$98.00 ➝ $115.006/4/2025HQYHealthEquityThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$94.00 ➝ $104.006/4/2025HQYHealthEquityRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $117.006/4/2025HQYHealthEquityJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$110.00 ➝ $117.006/4/2025HQYHealthEquityBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$110.00 ➝ $125.005/30/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$104.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.15B7.93$2.27 per share36.90$5.38 per share15.59HAEHaemonetics$1.36B2.69$7.14 per share10.67$16.34 per share4.66HQYHealthEquity$1.20B7.45$4.31 per share23.96$24.40 per share4.24LNTHLantheus$1.53B3.67$7.17 per share11.34$15.65 per share5.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.3462.6034.091.7712.90%30.05%10.00%7/30/2025 (Estimated)HAEHaemonetics$167.68M$3.3123.0315.121.2512.32%26.37%9.22%8/7/2025 (Estimated)HQYHealthEquity$96.70M$1.3775.6436.391.579.80%11.01%6.77%9/2/2025 (Estimated)LNTHLantheus$312.44M$3.5223.0812.88N/A16.55%36.99%20.55%7/30/2025 (Estimated)Latest HAE, DXCM, HQY, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025DXCMDexCom$0.45N/AN/AN/A$1.13 billionN/A7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A6/3/2025Q1 2026HQYHealthEquity$0.81$0.97+$0.16$0.61$322.25 million$330.80 million5/8/2025Q4 2025HAEHaemonetics$1.22$1.24+$0.02$1.17$329.38 million$330.60 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/1/2025Q1 2025DXCMDexCom$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AHQYHealthEquityN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.551.501.32HAEHaemonetics1.121.620.99HQYHealthEquity0.504.064.06LNTHLantheus0.495.745.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%HAEHaemonetics99.67%HQYHealthEquity99.55%LNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%HAEHaemonetics1.84%HQYHealthEquity1.50%LNTHLantheus2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.11 million390.85 millionOptionableHAEHaemonetics3,02348.04 million47.16 millionOptionableHQYHealthEquity3,12086.47 million85.18 millionOptionableLNTHLantheus70069.19 million67.80 millionOptionableHAE, DXCM, HQY, and LNTH HeadlinesRecent News About These CompaniesLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Buy" from AnalystsJuly 8 at 4:25 AM | marketbeat.com1 Safe-and-Steady Stock on Our Watchlist and 2 to Keep Off Your RadarJuly 7 at 6:17 AM | finance.yahoo.comNew York State Teachers Retirement System Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 5 at 4:26 AM | marketbeat.comAllspring Global Investments Holdings LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 3, 2025 | marketbeat.comLantheus’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJuly 2, 2025 | msn.comKeybank National Association OH Has $56.30 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 2, 2025 | marketbeat.comLantheus Seems Worth The (Very Real) RisksJuly 1, 2025 | seekingalpha.comContrasting RBC Life Sciences (OTCMKTS:RBCL) and Lantheus (NASDAQ:LNTH)July 1, 2025 | americanbankingnews.comPeregrine Capital Management LLC Sells 5,148 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)June 30, 2025 | marketbeat.comRiley Maintains ‘Buy’ Rating on Lantheus Holdings, Inc. (LNTH); Lowers PTJune 29, 2025 | insidermonkey.comLisanti Capital Growth LLC Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 29, 2025 | marketbeat.comLantheus Holdings Inc Analysis & Opinion (LNTH) - Investing.comJune 28, 2025 | investing.comLNTH - Lantheus Holdings Inc Trailing Returns | MorningstarJune 26, 2025 | morningstar.comMJanney Montgomery Scott LLC Increases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 26, 2025 | marketbeat.comSpotting Winners: Lantheus (NASDAQ:LNTH) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q1June 25, 2025 | msn.comLantheus Holdings, Inc. (LNTH) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comLantheus to Present New Oncology Radiodiagnostic Data at SNMMI MeetingJune 24, 2025 | msn.comB. Riley Issues Pessimistic Forecast for Lantheus (NASDAQ:LNTH) Stock PriceJune 23, 2025 | marketbeat.comExchange Traded Concepts LLC Raises Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 21, 2025 | marketbeat.comLantheus Holdings (NasdaqGM:LNTH) Joins FIBRE Consortium To Transform Fibrotic Disease TreatmentJune 21, 2025 | uk.finance.yahoo.comRiverwater Partners LLC Has $1.40 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHAE, DXCM, HQY, and LNTH Company DescriptionsDexCom NASDAQ:DXCM$83.86 +0.92 (+1.11%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Haemonetics NYSE:HAE$76.22 +1.09 (+1.44%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.HealthEquity NASDAQ:HQY$103.34 +1.51 (+1.48%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.Lantheus NASDAQ:LNTH$81.26 +2.07 (+2.61%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.